Atrophic vaginitis signs, symptoms, and better outcomes

Nurse Practitioner

Volumn 36, Issue 1, 2011, Pages 22-28

  Reimer, Annabelle ^a   Johnson, Laura ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b Lundar Health Centre   (Canada)

Author keywords

Atrophic vaginitis; Hypoestrogenic state; Menopause, vaginal atrophy

Indexed keywords

ATROPHY; FEMALE; HUMAN; NURSE PRACTITIONER; NURSING EDUCATION; PATHOLOGY; PATHOPHYSIOLOGY; POSTMENOPAUSE; REVIEW; TREATMENT OUTCOME; VAGINITIS; WOMEN'S HEALTH;

ATROPHY; EDUCATION, NURSING, CONTINUING; FEMALE; HUMANS; NURSE PRACTITIONERS; POSTMENOPAUSE; TREATMENT OUTCOME; VAGINITIS; WOMEN'S HEALTH;

EID: 84855495162     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000391175.25008.ae     Document Type: Article

References (33)

1. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause. 2009;16(4):719-727.
2. Birkhauser MH, Reinecke I. Current trends in hormone replacement therapy: perceptions and usage. Climacteric. 2008;11(3):192-200.
3. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997;314(4):228-231.
4. Bachmann G, Santen RJ. Treatment of vaginal atrophy. UpToDate. 2009.
5. Crandall C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J Womens Health (Larchmt). 2002;11(10):857-877.
6. Bachmann G, Santen RJ. Clinical manifestations and diagnosis of vaginal atrophy. UpToDate. 2009.
7. Doyle H. Effective topical treatments for atrophic vaginitis. JAAPA. 2006;19(10):33-38.
8. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111(1):67-76.
9. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines: the detection and management of vaginal atrophy: number 145, May 2004. Int J Gynecol Obstet. 2005;88(2):222-228.
10. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3 pt 1):355-369.
11. Buttaro T, Trybulski J, Bailey MA, Starr NB, Blosser CG. Primary Care: A Collaborative Practice. 3rd ed. St. Louis, MO: Mosby; 2008.
12. Palmer AR, Likis FE. Lactational atrophic vaginitis. J Midwifery Womens Health. 2003;48(4):282-284.
13. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005;52(suppl 1):S46-S52.
14. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopause and postmenopausal women. J Sex Med. 2005;2(suppl 3):154-165.
15. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning. J Sex Med. 2009;6(3):603-616.
16. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008;112(5):1053-1060.
17. Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med. 2008;6(1):30-39.
18. Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician. 2004;70(11):2125-2132.
19. Pinkerton JV, Stovall DW, Kightlinger RS. Advances in the treatment of menopausal symptoms. Womens Health (Lond, Engl). 2009;5(4):361-384.
20. Brand AH. The woman with postmenopausal bleeding. Aust Fam Physician. 2007;36(3):116-120.
21. Telner DE, Jakubovicz D. Approach to diagnosis and management of abnormal uterine bleeding. Can Fam Physician. 2007;53(1):58-64.
22. Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in postmenopausal women: a critical review. Pain Res Manag. 2008;13(3):243-254.
23. Kaplan C. Assessing and managing female sexual dysfunction. Nurse Pract. 2009;34(1):42-48.
24. Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol. 2008;51(3):549-555.
25. Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause: cytology, histology, and pH as methods of assessment. Maturitas. 1995;21(1):51-56.
26. Bateson DJ, Weisberg E. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears. Menopause. 2009;16(4):765-769.
27. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab. 2008;93(12):4567-4575.
28. Nothnagle M, Taylor SJ. Vaginal estrogen preparations for relief of atrophic vaginitis. Am Fam Physician. 2004;69(9):2111-2112.
29. Cicinelli E. Intravaginal oestrogen and progestin administration: advantages and disadvantages. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):391-405.
30. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009;16(4):735-741.
31. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500.
32. Ballagh SA. Vaginal rings for menopausal symptom relief. Drugs Aging. 2004;21(12):757-766.
33. Lynch C. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health (Larchmt). 2009;18(10):1595-1606.